ArticleCancer biotherapy & radiopharmaceuticals2010

Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5).

Andres Forero-Torres et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.